Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 135062-02-1 | Product Number: R0179
Repaglinide
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic Acid
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 200MG |
$112.00
|
Contact Us | 1 | 16 |
|
| 1G |
$329.00
|
1 | Contact Us | 33 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | R0179 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__7H__3__6N__2O__4 = 452.60 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 135062-02-1 |
| Reaxys Registry Number | 8238956 |
| PubChem Substance ID | 253661221 |
| Merck Index (14) | 8136 |
| MDL Number | MFCD00906179 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 131.0 to 135.0 °C |
| Specific rotation [a]20/D | +7.0 to +10.0 deg(C=1,MeOH) |
Properties (reference)
| Melting Point | 133 °C |
| Specific Rotation | 9° (C=1,MeOH) |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. H362 : May cause harm to breast-fed children. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | DI0876305 |
Transport Information:
| HS Number | 2933.39.9200 |
Application
Repaglinide: A Fast-Acting Insulin-Releasing Agent
Repaglinide, a carbamoylmethyl benzoic acid derivative, is a fast-acting insulin-releasing agent. Its mechanism of action is partly similar to that of the sulfonylureas such as glibenclamide [G0382] which binds to the sulfonylurea binding sites on pancreatic β-cells resulting in reducing blood glucose. For details, repaglinide stimulates the release of insulin from pancreatic β-cells by closing ATP-sensitive potassium channels, which results in the opening of calcium channels in the β-cells. Repaglinide is metabolized by CYP2C8 and CYP3A4 enzymes. Repaglinide is used for the treatment of type 2 diabetes. For your reference, [E0928] is a synthetic intermediate of repaglinide. (The product is for research purpose only.)
References
- Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes
- Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus (a review)
- Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus
- Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin
- Ionization, lipophilicity and solubility properties of repaglinide
- Determination of repaglinide in pharmaceutical formulations by HPLC with UV detection
PubMed Literature
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.